Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,208.2
16.0 (0.50%)

 

  • STI Straits Times Index
    3,208.2
    16.0 (0.50%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,591.3
    -0.9 (-0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,617.9
    151.0 (0.57%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,913.8
    10.2 (0.35%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,206.0
    167.4 (0.73%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,117.4
    -
    Index delayed 10 minutes
  • KOR KOSPI
    2,103.6
    7.0 (0.34%)
    Index delayed 20 minutes
  • XAO XAO
    6,821.6
    43.9 (0.65%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 179.1M
  • Value: 154.8M
  • Rise: 120
  • Fall: 46
  • Unch: 663

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.161+0.007
Tritech0.037-0.006
YZJ Shipbldg SGD1.010+0.015
Dyna-Mac0.125+0.007
Golden Agri-Res0.240+0.005
LION-PHILLIP S-REIT1.140+0.003
Mapletree Com Tr2.310+0.020
Citic Envirotech0.535-
GSS Energy0.088+0.006
Spackman0.015+0.001

World Indices

World Indices
Name Last Change
Nasdaq 8,506.2 -20.5
HSI 26,621.2 +154.3
HSCEI 10,523.3 +73.0
Jakarta 6,117.4
Nikkei 225 23,204.6 +166.0
SSE Comp 2,913.7 +10.1
Shanghai A 3,052.7 +10.6
Shanghai B 255.1 +0.1
PSE Comp 0.0
KOSPI 2,103.4 +6.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

AGILENT TECHNOLOGIES INC AGILENT TECHNOLOGIES INC
Updated on 21 Nov 2019 (End of trading day)
Last (USD): 78.300 Change: -0.220 High: 78.970 Remarks: -
Change (%): -0.28 Low: 77.310
Open 78.970 Yesterday's Close 78.52
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 2,137,398 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 1.02111 Trailing EPS (USD) e 3.46401 NAV (USD) b 15.3392
PE a 76.681 Trailing PE f 22.604 Price / NAV b 5.1046
Dividend (USD) d 0.612431 Cash In Hand (USD) g 5.7033 Issued & Paid-up Shares c 309,468,000
Dividend Yield (%) d 0.782 Price / Cash In Hand g 13.729 Treasury Shares h -
Beta - 75 Daysi 1.382 R-Squared - 75 Days(%)i 41.57 Market Cap (M) 24,231.344
Beta - 500 Daysi 1.037 R-Squared - 500 Days (%)i 26.69 Enterprise Value (M) 24,264.344
Piotroski F Score 7 Exchange Code A Par Value ( $ ) n.a.
52 Weeks Volatility (%) 25.90 Free Float (%) 99.5
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 04 Sep 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 03 Sep 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference AGILENT TECHNOLOGIES INC NYSE 24,231.344 76.681 22.604 5.1046 0.782
Industry Biotechnology NYSE 4,899.030 16504.313 47.330 4.8182 0.645
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 2,705.614 43.152 629.213 2.6141 -
Local Peer MYOVANT SCIENCES LTD NYSE 1,114.026 - - 64.5714 -
Local Peer KADMON HLDGS INC NYSE 620.984 - - 16.2525 -
Local Peer ARCUS BIOSCIENCES INC NYSE 365.496 - - 2.0623 -
Local Peer ENZO BIOCHEM INC NYSE 133.160 53.496 53.499 1.5479 -
Global Peer AMGEN INC NASDAQ 135,366.999 16.127 16.780 12.3883 2.456
Global Peer CSL ASX 121,182.756 45.168 45.168 16.1941 0.994
Global Peer GILEAD SCIENCES INC NASDAQ 83,158.310 15.244 30.879 4.0360 3.515
Global Peer CELGENE CORP NASDAQ 77,035.923 19.040 13.101 6.3735 -
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 55,415.825 26.434 25.850 10.5486 -
Global Peer BIOGEN INC NASDAQ 52,050.299 11.748 9.647 3.7190 -
Global Peer ILLUMINA INC NASDAQ 45,988.950 55.677 47.265 10.3602 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 38,514.230 15.756 17.962 3.6665 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,238.003 312.345 16.485 2.3380 -
Other Global Peers SEATTLE GENETICS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), ALNYLAM PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), MODERNA INC (NASDAQ), 10X GENOMICS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), GENSCRIPT BIO (HKEx), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), REPLIGEN CORP (NASDAQ), Lonza (SGX), SPARK THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), 3SBIO (HKEx), BLUEPRINT MEDICINES CORP (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), UNIQURE N.V. (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), XENCOR INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), INSMED INC (NASDAQ), HAOHAI BIOTEC (HKEx), AIMMUNE THERAPEUTICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), EPIZYME INC (NASDAQ), REGENXBIO INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), VIELA BIO INC (NASDAQ), ARVINAS INC (NASDAQ), VERACYTE INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), KODIAK SCIENCES INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), RADIUS HEALTH INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALECTOR INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), INTREXON CORP (NASDAQ), VIVA BIOTECH (HKEx), LUMINEX CORP(DEL) (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), POLYNOVO LIMITED (ASX), NANOSTRING TECHNOLOGIES INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ASCENTAGE-B (HKEx), ZIOPHARM ONCOLOGY INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), AVITA MEDICAL LTD (ASX), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), CORTEXYME INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ASCLETIS-B (HKEx), TRANSLATE BIO INC (NASDAQ), MESOBLAST LTD (ASX), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SINOMAB BIO-B (HKEx), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), AGENUS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), XBIOTECH INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), RETROPHIN INC (NASDAQ), CYTOKINETICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ESSEX BIO-TECH (HKEx), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), AVROBIO INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), ARDELYX INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MERUS B V (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MACROGENICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), BELLUS HEALTH INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), MEDICINOVA INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), PUMA BIOTECHNOLOGY INC (NASDAQ), TELIX PHARMACEUTIC (ASX), CASI PHARMACEUTICALS INC (NASDAQ), NEXT SCIENCE LTD (ASX), BIOCRYST PHARMACEUTICALS INC (NASDAQ), LEE'S PHARM (HKEx), MOLECULAR TEMPLATES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), PERSONALIS INC (NASDAQ), GERON CORP (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SERES THERAPEUTICS (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), KAMADA (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), CHIASMA INC (NASDAQ), DPHARMA (Bursa), ATHERSYS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), PFENEX INC (NYSE American), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), AFFIMED N V (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NANOVIRICIDES INC (NYSE American), JOUNCE THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), BBI LIFE SCI (HKEx), LIMINAL BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), MERSANA THERAPEUTICS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), UNI-BIO GROUP (HKEx), IMUGENE LIMITED (ASX), FORTRESS BIOTECH INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CHIMERIX INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), IMV INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), SESEN BIO INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), NANTKWEST INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), BIOXCEL THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ARAVIVE INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PHYLOGICA LIMITED (ASX), AVEO PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), ADURO BIOTECH INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), 22ND CENTURY GROUP INC (NYSE American), COHBAR INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), T2 BIOSYSTEMS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CEL-SCI CORP (NYSE American), OTONOMY INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), IMMUTEP LTD (ASX), SYNLOGIC INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), INFLARX N V (NASDAQ), VERMILLION INC (NASDAQ), VERASTEM INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), TREVENA INC (NASDAQ), EQUILLIUM INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ORTHOCELL LIMITED (ASX), CATABASIS PHARMACEUTICALS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ORGENESIS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CURIS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), INMUNE BIO INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), CT ENTERPRISE (HKEx), DIAMEDICA THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), PORT (SET), BELLICUM PHARMACEUTICALS (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), NEON THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), RESTORBIO INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), EVOGENE LTD (NASDAQ), BIONOMICS LTD (ASX), SAVARA INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), NOVITA HEALTHCARE LTD (ASX), OUTLOOK THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), ZAFGEN INC (NASDAQ), REGENT PACIFIC (HKEx), APTEVO THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), BIOSINO BIO-TEC (HKEx), BIOCARDIA INC (NASDAQ), RHINOMED LIMITED (ASX), ALIMERA SCIENCES INC (NASDAQ), BIOTRON (ASX), MEMPHASYS LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ORAGENICS INC (NYSE American), SEELOS THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), ISORAY INC (NYSE American), EXTRAWELL PHAR (HKEx), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ANTEOTECH LIMITED (ASX), AZURRX BIOPHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), SENESTECH INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), REGENEUS LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CO DIAGNOSTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), IMMURON LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), TOCAGEN INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), PRECIPIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), VAXART INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), Suntar Eco-City^ (SGX), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ADALTA LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), BIOCEPT INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), IBIO INC (NYSE American), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), HAO WEN HLDGS (HKEx), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ADVAXIS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), MEGASUN (Bursa), NOVABAY PHARMACEUTICALS INC (NYSE American), AUSTRALIAN PRIMARY HEMP LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ACHIEVE LIFE SCIENCE INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), MGRC (Bursa), CYCLACEL PHARMA IN (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), BIOXYNE LIMITED (ASX), TBG DIAGNOSTICS LTD (ASX), XENETIC BIOSCIENCES INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), MEDIBIO LIMITED (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), OPGEN INC (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), QT Vascular (SGX), ENDRA LIFE SCIENCES INC (NASDAQ), OCUGEN INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AIM IMMUNOTECH INC (NYSE American), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), BPH ENERGY LIMITED (ASX), PHIO PHARMACEUTICALS CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+1.540
+2.01 %
10 Days -+2.390
+3.15 %
20 Days -+3.300
+4.40 %
Medium Term Return 3 Months 0.164+6.560
+9.37 %
6 Months 0.328+10.600
+16.14 %
1 Year 0.656+10.580
+16.59 %
Long Term Return 2 Years 1.252+9.610
+15.81 %
3 Years 1.780+33.650
+79.35 %
5 Years 2.640+35.560
+89.38 %
Annualised Return Annualised --
+13.62 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 62.000 - 82.270 Change From 1 Year Low +16.300 % Change From 1 Year Low (%) +26.29
Change From 1 Year High -3.970 % Change From 1 Year High (%) -4.83
2 Years Range 60.420 - 82.270 Change From 2 Years Low +17.880 % Change From 2 Years Low (%) +29.59
Change From 2 Years High -3.970 % Change From 2 Years High (%) -4.83
5 Years Range 33.115 - 82.270 Change From 5 Years Low +45.185 % Change From 5 Years Low (%) +136.45
Change From 5 Years High -3.970 % Change From 5 Years High (%) -4.83
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Nov 2019 78.970 78.970 77.310 78.300 2,137,398 -
20 Nov 2019 79.160 79.360 78.210 78.520 2,429,830 -
19 Nov 2019 78.170 79.490 77.840 79.290 1,691,246 -
18 Nov 2019 78.140 78.500 77.500 77.940 1,641,215 -
15 Nov 2019 76.930 78.310 76.610 78.260 1,694,965 -
14 Nov 2019 77.210 77.450 76.480 76.760 1,113,519 -
13 Nov 2019 76.820 77.500 76.560 77.160 1,104,429 -
12 Nov 2019 77.000 77.550 76.720 77.050 1,008,400 -
11 Nov 2019 76.250 76.850 76.130 76.850 1,149,169 -
08 Nov 2019 75.900 76.650 75.650 76.640 1,231,456 -
07 Nov 2019 76.340 76.380 75.684 75.910 860,939 -
06 Nov 2019 75.700 75.940 74.940 75.790 1,355,737 -
05 Nov 2019 76.820 76.910 75.470 75.550 2,362,034 -
04 Nov 2019 77.680 77.845 76.730 76.740 996,375 -
01 Nov 2019 76.510 77.350 76.315 76.970 1,090,084 -
31 Oct 2019 76.000 76.120 75.100 75.750 970,472 -
30 Oct 2019 76.040 76.150 75.240 76.120 914,825 -
29 Oct 2019 75.050 76.680 74.940 76.170 1,110,403 -
28 Oct 2019 75.690 76.555 75.690 76.150 1,143,869 -
25 Oct 2019 74.700 75.970 74.130 75.390 835,050 -
24 Oct 2019 75.030 75.110 74.460 75.000 1,582,478 -
23 Oct 2019 75.020 75.890 74.680 74.980 1,785,190 -
Summary
Current 2 Weeks
(08 Nov 2019 to 21 Nov 2019)
75.900 79.490 75.650 78.300 15,201,627 -
Previous 2 Weeks
(25 Oct 2019 to 07 Nov 2019)
74.700 79.490 74.130 75.910 11,639,788 -
4 Weeks from
(27 Sep 2019 to 24 Oct 2019)
77.020 79.490 75.650 75.000 33,366,350 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.